Background: Genomic structural variants (SVs) can affect many genes and regulatory 26 elements. Therefore, the molecular mechanisms driving the phenotypes of patients with 27 multiple congenital abnormalities and/or intellectual disability carrying de novo SVs are 28 frequently unknown. 29
It has been shown that the use of computational methods based on combining 84 phenotypic information from the Human Phenotype Ontology (HPO) database 85 ("phenomatching") with previously published chromatin interactions datasets can improve the 86 interpretation of the molecular consequences of de novo SVs [16] [17] [18] . These approaches 87 have largely been based on data derived from a small set of cell types and techniques. Here, 88
we further expand these in silico approaches by integrating detailed phenotype information 89 with genome-wide chromatin conformation datasets of many different cell types. By combining 90 this method with whole genome and transcriptome sequencing we predicted which genes are 91 affected by the SVs and which of these genes have likely been involved in the development 92 of the disease phenotype (e.g. candidate driver genes). Accurate characterization of the 93 effects of SVs on genes can be beneficial for the prediction of potential clinical relevance of 94 the SVs. Detailed interpretation of the molecular effects of the SVs helped to identify candidate 95 driver genes in 16 out of 39 included patients who had an inconclusive diagnosis after regular 96 genetic testing. By applying the computational method on larger cohorts of patients with de 97 Additional File 2: Table S1 ). The parents of each of the patients were healthy, suggesting a 109 de novo or recessive origin of the disease phenotypes. All individuals carried de novo SVs 110 which were previously detected by ArrayCGH, SNP arrays, karyotyping or long-insert mate-111 pair sequencing (Additional File 1: Fig. S1a ). First, we performed whole genome sequencing 112 (WGS) for all individuals in the cohort to screen for potential pathogenic genetic variants that 113 were not detected by the previously performed genetic tests. No known pathogenic single 114 nucleotide variants (SNVs) were detected in the individuals analysed by patient-parents trio-115 based WGS (individuals P1 to P20), except for one pathogenic SNV that is associated with a 116 part (haemophilia) of the phenotype of individual P1. A total of 46 unbalanced and 219 117 balanced de novo SVs were identified in the genomes of the individuals (Fig.1b , Additional 118 File 1: Fig. S1b , Additional File 2: Table S2 ). The detected SVs ranged from simple SVs to 119 very complex genomic rearrangements that ranged from 4 to 40 breakpoint junctions per 120 individual. Importantly, WGS confirmed all previously detected de novo SVs and revealed 121 additional complexity of the SVs in 7 (39%) of the 18 cases who were not studied by WGS-122 based techniques before ( Fig. 1c-d , Additional File 2: Table S2 ). In half of the cases with 123 previously identified de novo copy number gains (4/8), the gains were not arranged in a 124 tandem orientation, but instead they were inserted in another genomic region, which can have 125 far-reaching consequences for accurate interpretation of the pathogenetic mechanisms in 126 these individuals ( Fig. 1d ) [22] [23] [24] . This suggests that the complexity of copy number gains in 127 particular is frequently underestimated by microarray analysis. For example, in one case (P11) 128 a previously detected 170 kb copy number gain from chromosome 9 was actually inserted into 129 chromosome X, 82 kb upstream of the SOX3 gene ( Fig. 1d , Additional File 1: Fig. S2 ). This 130 inserted fragment contains a super-enhancer region that is active in craniofacial development 131 6 137 In silico phenomatching approach links directly affected genes to phenotypes 138 Subsequently, we determined if the phenotypes of the patients could be explained by direct 139 effects of the de novo SVs, most of which were previously classified as a variant of unknown 140 significance (VUS), on genes. In total, 332 genes are directly affected (deleted, duplicated or 141 truncated) by the SVs in the cohort (Additional File 1: Fig. S1d ). The Phenomatch tool was 142 used to match the HPO terms associated with these genes with the HPO terms used to 143 describe the phenotypes of the individuals [16, 17] . Genes were considered as candidate driver 144 genes based on the height of their Phenomatch score, the number of phenomatches between 145 the HPO terms of the gene and the patient, recessive or dominant mode of inheritance, Loss 146 of Function constraint score (pLI) [31] , Residual Variation Intolerance Score (RVIS) [32] and 147 the presence in OMIM and/or DD2GP [33] databases (Table 1) . Directly affected genes 148 strongly or moderately associated with the phenotype are classified as tier 1 (T1) and tier 2 149 (T2) candidate driver genes, respectively ( Fig. 2a , Table 1 ). Genes with limited evidence for 150 contribution to the phenotype are reported as tier 3 (T3) genes. In the cohort of 39 patients, 151 this approach prioritized 2 and 13 of the 332 directly affected genes as T1 and T2 candidate 152 drivers, respectively (Fig. 2b) . In three cases, the HPO terms of the identified T1/T2 candidate 153 driver genes could be matched to more than 75% of the HPO terms assigned to the patients, 154
indicating that the effects of the SVs on these genes can explain most of the phenotypes of 155 these patients. (Additional file 2: Table S3 ). In six other cases, directly affected T1/T2 156 candidate drivers were identified that were only associated with a part of the patient's 157 phenotypes (Additional file 2: Table S3 ). 158
Subsequently, we performed RNA sequencing on primary blood cells or 159 lymphoblastoid cell lines derived from the individuals to determine the impact of de novo SVs 160 on RNA expression of candidate driver genes. RNA sequencing confirmed that most 161 expressed genes directly affected by de novo deletions show a reduced RNA expression (97 162 of 107 genes with a median reduction of 0.46-fold compared to non-affected individuals) ( Fig.  163   2d ). Although duplicated genes show a median 1.44-fold increase in expression, only 14 of 43 164 (~30%) of them are significantly overexpressed compared to expression levels in non-affected 165 individuals. In total, 87 genes are truncated by SVs and four of these are classified as T1/T2 166 candidate drivers. The genomic rearrangements lead to 12 possible fusions of truncated 167 genes and RNA-seq showed an increased expression for two gene fragments due to formation 168 of a fusion gene (Additional file 1: Fig. S3 , Additional file 2: Table S4 ). However, none of the 169 genes involved in the formation of fusion genes were associated with the phenotypes of the 170 patients, although we cannot exclude an unknown pathogenic effect of the newly identified 171 fusion genes. We could detect expression for three deleted and two duplicated T1/T2 172 candidate drivers and these were differentially expressed when compared to controls. The 173
RNA sequencing data suggests that most genes affected by de novo deletions show reduced 174 RNA expression levels and limited dosage compensation. However, the observed increased 175 gene dosage by de novo duplications does not always lead to increased RNA expression, at 176 least in blood cells of patients. 177
178

Prediction of positional effects of de novo SVs on neighbouring genes 179
In 28 of the included cases (72%) our prioritization method did not predict T1/T2 candidate 180 driver genes that are directly affected by the de novo SVs. Therefore, we investigated 181 positional effects on the genes surrounding the de novo SVs to explain the phenotypes in 182 those cases that were not fully explained by directly affected candidate driver genes. We 183 extended our candidate driver gene prioritization analysis by including all the protein-coding 184 genes located within 2 Mb of the breakpoint junctions, as most chromatin interactions are 185 formed between loci that are less than 2Mb apart from each other [34] . Of the 2,754 genes 186 adjacent to the SVs, 117 are moderately to strongly associated with the specific phenotypes 187 of the individuals based on phenotype association analysis. However, this association with the 188 phenotype does not necessarily mean that these genes located within 2Mb of the breakpoint 189 junctions are really affected by the SVs and thus contributing to the phenotype. To determine 190 if the regulation of these genes was affected, we first evaluated RNA expression levels of 191 those genes. Three-quarters (81/117) of the genes linked to the phenotypes were expressed, 192 but only 9 of these showed reduced or increased expression ( Fig. 2d ). However, RNA 193 expression in blood may not always be a relevant proxy for most neurodevelopmental 194 phenotypes [35, 36] . Therefore, we developed an extensive in silico strategy to predict potential 195 disruption of the regulatory landscape of the genes surrounding the SVs (Additional file 1: Fig.  196 S4). Because the interactions between genes and their regulatory elements are cell-type 197 specific a large collection of tissue-specific Hi-C, TAD, promoter capture Hi-C (PCHiC), DNase 198 hypersensitivity site (DHS), RNA and ChIP-seq datasets was included (Additional file 2: Table  199 S5). Several embryonic and neural cell type (such as fetal brain and neural progenitor cells) 200 datasets were included that may be especially relevant to study the neurodevelopmental 201 phenotypes in our cohort. 202
For each gene, we selected the TAD it is located in [37-39], the PCHiC interactions 203 with its transcription start site [40-43] and its DHS connections [44] for each assessed cell 204 type and overlapped these features with the breakpoint junctions of the SVs to determine the 205 proportion of disrupted genomic interactions (Methods, Additional file 1: Fig. S4 ). We also 206 counted the number of enhancers (which are active in cell types in which the genes show the 207 highest RNA expression [45] ) that are located on disrupted portions of the TADs. Additionally, 208
we performed virtual 4C (v4C) for each gene by selecting the rows of the normalized Hi-C 209 matrices containing the transcription start site coordinates of the genes as viewpoints, 210 because the coordinates of TAD boundaries can be dependent on the calling method and the 211 resolution of the Hi-C [46-48] and because a significant portion of genomic interactions 212 crosses TAD boundaries [9] . Integrated scores for TAD disruption, v4C disruption, potential 213 enhancer loss, disruption of PCHiC interactions and DHS connections were used to calculate 214 a positional effect support score for each gene (Additional file 1: Fig. S4 ). Finally, indirectly 215 affected genes were classified as tier 1, 2 or 3 candidate drivers based on a combination of 216 their association with the phenotype and their support score ( Fig. 2a , Table 1 ). 217
Of the 117 genes that were associated with the phenotypes and located within 2 Mb 218 of the SVs, 16 genes were predicted to be affected by the SVs based on the in silico analysis 219 and therefore classified as T1/T2 candidate driver gene (Fig. 2b) . The validity of the approach 220 was supported by the detection of pathogenic positional effects identified in previous studies. 221
For example, the regulatory landscape of SOX9 was predicted to be disturbed by a 222 translocation 721 Kb upstream of the gene in individual P5, whose phenotype is mainly 223 characterized by acampomelic campomelic dysplasia with Pierre-Robin Syndrome ( Our approach predicted positional effects on T1/T2 candidate driver genes in 10 242 included cases (26%). Most of these predicted positional effects were caused by breakpoint 243 junctions of balanced SVs, suggesting that these effects may be especially important for 244 balanced SVs. 245
246
Prediction of driver genes improves molecular diagnosis 247
By combining both directly and indirectly affected candidate drivers per patient we found 248 possible explanations for the phenotypes of 16/39 (41%) complex and/or previously unsolved 249 cases ( Fig. 3a , Additional file 2: Table S3 ). Interestingly, in eight cases we found evidence for 250 multiple candidate drivers that are individually only associated with part of the phenotype, but 251 together may largely explain the phenotype (Fig. 3b ). For example, we identified four 252 candidate drivers in individual P25, who has a complex phenotype characterized by 253 developmental delay, autism, seizures, renal agenesis, cryptorchidism and an abnormal facial 254 shape ( Fig. 3c ). This individual has complex genomic rearrangements consisting of six 255 breakpoint junctions and two deletions of ~10 Mb and ~0.6 Mb on three different chromosomes 256 ( Fig. 3d ). The 6q13q14.1 deletion of ~10 Mb affects 33 genes including the candidate drivers 257 PHIP and COL12A1, which have been associated with developmental delay, anxiety and facial 258 dysmorphisms in other patients [60, 61] . In addition to the two deleted drivers, two genes 259 associated with other parts of the phenotype were predicted to be affected by positional effects 260 ( Fig. 3e ). One of these genes is TFAP2A, whose TAD (characterized by a large gene desert) 261 and long-range interactions overlap with a translocation breakpoint junction. Rearrangements 262 affecting the genomic interactions between TFAP2A and enhancers active in neural crest cells 263 located in the TFAP2A TAD have recently been implicated in branchio-oculofacial syndrome 264
[62]. The regulation of BMP2, a gene linked to agenesis of the ribs and cardiac features, is 265 also predicted to be disturbed by a complex SV upstream of this gene [63,64]. Altogether, 266 these candidate driver genes may have jointly contributed to the phenotype of this individual 267 ( Fig. 3d ). This case illustrates the challenge of identifying the causal genes driving the 268 phenotypes of patients with structural rearrangements and highlights the notion that multiple 269 genes should be considered for understanding the underlying molecular processes and 270 explaining the patient's phenotype. 271
272
In silico driver gene prediction in larger patient cohorts 273
Our candidate driver prioritization approach identified many candidate drivers in previously 274 unresolved cases, but these complex cases may not be fully representative for the general 275 patient population seen in clinical genetic diagnostics. Therefore, we applied our prediction 276 method to two larger sets of patients with de novo SVs to further assess the validity and value 277 of the approach. We focused on the genes located at or within 1 Mb of the SVs, because most 278 of the candidate driver genes we identified in our own patient cohort were located within 1 Mb 279 of an SV breakpoint junction (Additional file 1: Fig. S5b ). First, we determined the effects of 280 largely balanced structural variants in 228 previously described patients (Additional file 1: Fig.  281 S7a) [51] . In 101 of the 228 (44%) cases the detected de novo SVs were previously classified 282 as pathogenic or likely pathogenic and in all but four of these diagnosed cases one or more 283 candidate driver genes have been proposed (Additional file 1: Fig. S7b ). Our approach 284 identified 46 T1 and 92 T2 candidate drivers out of 7406 genes located within 1 Mb of the SVs 285 (Additional file 1: Fig. S7c ,d, Additional file 2: Table S7 ). More than half (85/138) of the 286 identified T1/T2 candidate drivers were not previously described as driver genes. In contrast, 287 23/114 (22%) previously described pathogenic or likely pathogenic drivers were classified as 288 T3 candidates and 38/114 (33%) were not reported as driver by our approach (Fig. 4a ), mostly 289 because the Phenomatch scores were below the threshold (46%) or because the genes were 290 not associated with HPO terms (41%) (Additional file 1: Positional effect on genes moderately to strongly associated with the phenotypes were 294 predicted in 63 (28%) of the cases with balanced SVs. 295
Subsequently, we also assessed the value of our driver prioritization approach for 296 individuals with unbalanced copy number variants. We collected genetic and phenotypic 297 information of 154 individuals with de novo copy number variants (<10 Mb) identified by clinical 298 array-based copy number profiling (Additional file 1: Fig. S7a ,b, Additional file 2: Table S6 ). 299
The CNVs in the majority (83%) of these individuals have been previously classified as 300 pathogenic according to clinical genetic diagnostic criteria (Additional file 1: Fig. S7b ). These 301 criteria are mostly based on the overlap of the CNVs with CNVs of other individuals with similar 302 phenotypes and the causative driver genes were typically not previously specified. Our method 303 identified T1/T2 candidate driver genes in 87/154 (56%) individuals, including 9/26 individuals 304 with CNVs previously classified as VUS ( Fig. 4a , Additional file 2: Table S7 ). Interestingly, 305 support for positional effects on candidate drivers was only found in 11% of the cases with 306
CNVs, suggesting that pathogenic positional effects are more common in patients with 307 balanced SVs than in patients with unbalanced SVs (Fig. 4b ). No driver genes were identified 308 for 39% of the previously considered pathogenic CNVs (based on recurrence in other 309 patients). In some cases, potential drivers may remain unidentified because of incompleteness 310 of the HPO database or insufficient description of the patient's phenotypes. However, given 311 the WGS results described for our patient cohort, it is also likely that some complexities of the 312 CNVs may have been missed by the array-based detection method. The data also suggests 313 that many disease-causing genes or mechanisms are still not known, and that some SVs are 314 incorrectly classified as pathogenic. 315 316 Discussion 317
About half of the patients with neurodevelopmental disorders do not receive a diagnosis after 318 regular genetic testing based on whole exome sequencing and microarray-based copy 319 number profiling [3] . Furthermore, the molecular mechanisms underlying the disease 320 phenotype often remain unknown, even when a genetic variant is diagnosed as (potentially) 321 pathogenic in an individual, as this is often only based on recurrence in patients with a similar 322 phenotype. Here, we applied an integrative method based on WGS, computational 323 phenomatching and prediction of positional effects to improve the diagnosis and molecular 324 understanding of disease aetiology of individuals with de novo SVs. 325
Our WGS-approach identified additional complexities of the de novo SVs previously 326 missed by array-based analysis in 7 of 18 cases, supporting previous findings that WGS can 327 have an added value in identifying additional SVs that are not routinely detected by 328 microarrays [24] . Our results indicate that duplications in particular are often more complex 329 than interpreted by microarrays, which is in line with previous studies [22, 65] . WGS can 330 therefore be a valuable follow-up method to improve the diagnosis particularly of patients with 331 copy number gains classified as VUS. Knowing the exact genomic location and orientation of 332 SVs is important for the identification of possible positional effects. 333
To systematically dissect and understand the impact of de novo SVs, we developed a 334 computational tool based on integration of HiC, RNA-seq and ChIP-seq datasets to predict 335 positional effects of SVs on the regulation of gene expression. We combined these predictions 336 with phenotype association information to identify candidate driver genes. In 9/39 of the 337 complex cases we identified candidate drivers that are directly affected by the break-junctions 338 of the SVs. Positional effects of SVs have been shown to cause congenital disorders, but their 339 significance is still unclear and they are not yet routinely screened for in genetic diagnostics 340 [14] . Our method predicted positional effects on genes associated with the phenotype in 25% 341 and 8% of all studied cases with balanced and unbalanced de novo SVs, respectively. 342
Previous studies estimated that disruptions of TAD boundaries may be the underlying cause 343 of the phenotypes of ~7.3% patients with balanced rearrangements [51] and of ~11.8% of 344 patients with large rare deletions [16] . Our method identified a higher contribution of positional 345 effects in patients with balanced rearrangements mainly because our method included more 346 extensive chromatin conformation datasets and also screened for effects that may explain 347 smaller portions of the phenotypes. Our method, although it incorporates most of all published 348 chromatin conformation datasets on untransformed human cells, focuses on disruptions of 349 interactions, which is a simplification of the complex nature of positional effects. It gives an 350 insight in the potential effects that lead to the phenotypes and prioritizes candidates that need 351 to be followed up experimentally, ideally in a developmental context for proofing causality. 352
SVs can affect many genes and multiple 'disturbed' genes may together contribute to 353 the phenotype. Indeed, in eight cases we found support for the involvement of multiple 354 candidate drivers that were affected by one or more de novo SVs. Nevertheless, in many of 355 the studied cases our method did not detect candidate drivers. This may be due to insufficient 356 data or knowledge about the genes and regulatory elements in the affected locus and/or due 357 to missing disease associations in the used databases. Single nucleotide variants and indels were called using GATK HaplotypeCaller. For individuals 424 P1 to P21 (whose parents were also sequenced), reads overlapping exons were selected and 425 the Bench NGS Lab platform (Agilent-Cartagenia) was used to detect possible pathogenic de 426 novo or recessive variants in the exome. De novo variants were only analysed if they affect 427 the protein structure of genes that are intolerant to missense and loss-of-function variants. Briefly, reads were aligned to the CRCh37/hg19 human reference genome using STAR 2.4.2a 437
[75]. The number of reads mapping to genes were counted using HTSeq-count 0.6.1 [76] . 438
Genes overlapping with SV breakpoints (eg truncated genes) were also analyzed separately 439 by counting the number of reads mapping to exons per truncated gene fragment (up-and 440 downstream of the breakpoint junction). RNA-seq data obtained from PBMCs (Individuals P1 441 to P22) and LCL cell lines (Individuals P23 to P39) were processed as separate datasets. The 442 R-package DESeq2 was used to normalize raw read counts and to perform differential gene 443 expression analysis for both datasets separately [77] . Genes with more than 0.5 reads per 444 kilobase per million mapped reads (RPKM) were considered to be expressed. 445
446
Gene annotation 447
Gene information (including genomic positions, Ensembl IDs, HGNC symbols and Refseq IDs) 448 was obtained from Ensembl (GRCh37) using the R-package biomaRt (v2.38) [78] . Genes 449 containing a RefSeq mRNA ID and a HGNC symbol were considered as protein-coding genes. 450
Genomic coordinates for the longest transcript were used if genes contained multiple RefSeq 451 mRNA IDs. The list of 19,300 protein-coding genes was further annotated with 1) pLI, 2) RVIS, 452
3) haploinsufficiency (HI) scores, 4) OMIM identifiers and 5) DD2GP information for each gene 453 (see Additional file 2: Table S5 for data sources). A phenotypic score based on these five 454 categories was determined for each gene. Modes of inheritance for each gene were retrieved 455 from the HPO and DD2GP databases. 456 457
Computational prediction of the effects of SVs on genes 458
For each patient, the protein-coding genes located at or adjacent (< 2Mb) to the de novo SV 459 breakpoint junctions were selected from the list of genes generated as described above. The 460 HPO terms linked to these genes in the HPO database [19-21] were matched to each 461 individual HPO term assigned to the patient and to the combination of the patient's HPO terms 462 using Phenomatch [16, 17] . For each gene, the number of phenomatchScores higher than 5 463 ("phenomatches") with each individual HPO term of a patient was calculated. The strength of 464 the association (none, weak, medium or strong) of each selected gene with the phenotype of 465 the patient was determined based on the total phenomatchScore, the number of 466 phenomatches, the mode of inheritance and the phenotypic score ( Fig. S4a, Table 1 ). 467
Subsequently, potential direct and indirect effects of the SVs (none, weak or strong) 468 on the genes were predicted (Fig. S4a, Table 1 ). The prediction analyses were based on 469 chromatin organization and epigenetic datasets of many different cell types obtained from 470 previous studies (see Additional file 2: Table S5 for data sources). 471
First, we determined which TADS of 20 different cell types overlapped with the de novo 472 SVs and which genes were located within these disrupted TADs [37-39] (Additional file 1: Fig.  473 S4b). To determine if the disrupted portions of the TADs contained regulatory elements that 474 may be relevant for the genes located in the affected TADs, we selected the three cell types 475 in which the gene is highest expressed based on RNA-seq data from the Encode/Roadmap 476 projects Genes were classified as T1 candidate drivers if they have a strong association with the 488 phenotype and are strongly affected by the SV. Genes classified as T2 candidate driver can 489 have a weak/medium phenotype association combined with a strong SV effect or they can 490 have a medium/strong phenotype association with a weak SV effect ( Fig. 2a , Table 1 ). 491 492 
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We would also like to thank the Hartwig Medical Foundation for providing whole genome 544 sequencing services. 545 546 rearrangements involving multiple duplications and an insertion of a fragment from chr14 into 774 chr3. Individual P11 has an insertion of a fragment of chr9 into chrX that was detected as a 775 copy number gain by array-based analysis (Fig. S2) . The detected copy number gains in 776 individuals P12 and P21 show an interspersed orientation instead of a tandem orientation. 777
Figures, tables and additional files 762
The translocation in patient P20 appeared to be more complex than previously anticipated 778 based on karyotyping results, showing 11 breakpoint junctions on three chromosomes. 779 Comparison between previous SV classifications with the strongest candidate driver (located 828 at or adjacent (<1 Mb) to these SVs) predicted by our approach. Two different patient cohorts, 829 one containing mostly balanced SVs [51] and one containing copy number variants, were 830 screened for candidate drivers. Our method identified T1/T2 candidate drivers for most SVs 831 previously classified as pathogenic or likely pathogenic. Additionally, the method detected 832 T1/T2 candidate drivers for some SVs previously classified as VUS, which may lead to a new 833 molecular diagnosis. b Quantification of the predicted effects of the SVs on proposed T1/T2 834 candidate driver genes per cohort. Individuals with multiple directly and indirectly affected 835 candidate drivers are grouped in the category described as "Both". Indirect positional effects 836 of SVs on genes contributing to phenotypes appear to be more common in patients with 837
balanced SVs compared to patients with copy number variants. Table S1 . Phenotype information of the 39 included patients with de 843 novo SVs . Table S2 . Coordinates of the de novo SV breakpoint junctions detected in the 39 844 individuals by WGS. Table S3 . Candidate driver genes detected for each included patient. 845 Table S4 . Fusion genes detected in the patients by RNA sequencing . Table S5 . List of 846 external data sources used in this study. The fragment (highlighted in yellow) is inserted 82 kb upstream of the SOX3 gene. This locus at chrX contains a palindromic sequence that is susceptible for formation of genomic rearrangement. Multiple patients with varying phenotypes and different insertions at this locus have been described [1] [2] [3] [4] [5] . The inserted fragment from chr9 contains multiple enhancers, including two previously described super-enhancer clusters (highlighted by red boxes), that are active in human (Palate (H), Carnegie stage 13) and mouse (Palate (M), embryonic day 11.5) craniofacial development and human cultured cranial neural crest cells (cNCC) [6] [7] [8] . The inserted enhancers may disturb the normal expression of the SOX3 gene and/or the surrounding genes, which may have led to the cleft palate phenotype in this patient. Genomic coordinates of mouse (mm9) embryonic craniofacial enhancers (determined by p300 ChIP-seq [6] ) were converted to hg19 coordinates using LiftOver (https://genome.ucsc.edu/cgi-bin/hgLiftOver). 
Fig. S4
Schematic overview of computational strategy used to predict positional effects. a The association of a gene at or adjacent to an SV with the patient-specific phenotype is based on the Phenomatch score, the number of phenomatches, mode of inheritance and the phenotypic score. Each gene has a fixed phenotypic score (ranging from 1 to 5) based on its pLI (>0. Information about the other patients was obtained from the following publications: T1+T2+T3 [9] ; T4 [10] ; C1+C2 [11] ; P1+P2 [12] ; V1 [13] ; R1 [14] ; H1+H2 [15] . 
Fig. S7
Overview of SVs and candidate drivers in two cohorts of patients with de novo SVs. a Quantification of previously identified de novo SVs in a cohort containing patients with mostly balanced SVs and a cohort containing patients with copy number variants (CNV). De novo translocations (TRA), inversions (INV) and intra-chromosomal rearrangements (INTRA) are most prevalent in the cohort of patients with balanced SVs. Some patients have complex genomic rearrangements (>3 SVs) including some deletions (DEL) or duplications (DUP). The cohort labelled as "CNV" consist of patients with relatively simple deletions and duplications (<10 Mb in size). b Number of patients whose de novo SVs were previously classified as pathogenic, likely pathogenic or variant of unknown significance (VUS) per cohort. c Total number of analysed genes per SV category in the two cohorts. Dup: Duplicated, Del: Deleted, Trunc: Truncated, Flank: Flanking SVs (<1 Mb). d Total number of predicted directly and indirectly affected candidate drivers per cohort. e Quantification of the genes that were previously classified as pathogenic or likely pathogenic (by Redin et al [16] ), but not identified as T1 or T2 candidate driver by our approach. These classification differences may be caused by a lack of HPO terms associated with the gene, low phenomatch scores below the threshold of our method, insufficient (weak) support for an effect of an SV on the gene detected by our method or a presumed recessive mode of inheritance. Predicted contributions of candidate drivers to the phenotypes of patients with balanced structural variants of unknown significance. T1/T2 candidate drivers were detected in 31 patients whose de novo SVs were previously classified as VUS by Redin et al [16] . The contributions to the phenotypes are based on the number of Phenomatch hits (phenomatchScore > 5) of the gene with each individual HPO term used to describe the phenotype of a patient. Shading indicates if there is relatively weak or strong evidence for an effect on the candidate driver.
